Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

NewAmsterdam Pharma (NAMSW) Interest & Investment Income (2023 - 2025)

Historic Interest & Investment Income for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to $6.7 million.

  • NewAmsterdam Pharma's Interest & Investment Income rose 5109.16% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 6996.81%. This contributed to the annual value of $16.9 million for FY2024, which is 4961.45% up from last year.
  • NewAmsterdam Pharma's Interest & Investment Income amounted to $6.7 million in Q3 2025, which was up 5109.16% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Interest & Investment Income registered a high of $7.4 million during Q1 2025, and its lowest value of $943000.0 during Q1 2023.
  • For the 3-year period, NewAmsterdam Pharma's Interest & Investment Income averaged around $4.5 million, with its median value being $4.5 million (2024).
  • The largest annual percentage gain for NewAmsterdam Pharma's Interest & Investment Income in the last 5 years was 22693.53% (2024), contrasted with its biggest fall of 557.12% (2024).
  • Over the past 3 years, NewAmsterdam Pharma's Interest & Investment Income (Quarter) stood at $2.7 million in 2023, then skyrocketed by 68.1% to $4.5 million in 2024, then soared by 49.68% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $7.1 million for Q2 2025, and $7.4 million during Q1 2025.